Month: October 2026

2026 China-France Scientific Symposium on Hematology and Immunology  was held in Beijing from September 11 to 13, 2026. Building on the longstanding tradition of hematology exchanges between China and France, this year's conference expanded its scope to the intersection of hematology and immunology, bringing together renowned experts from both countries to explore scientific advances and exchange perspectives. On this occasion, Oncology Frontier – Hematology Frontier invited Professor Suning Chen of The First Affiliated Hospital of Soochow University to discuss the standardized diagnosis and treatment of acute myeloid leukemia (AML) in young adults. Professor Chen examined the distinctive biological characteristics, treatment strategies, and prognostic features of AML in this population and shared valuable clinical insights into the prospects for targeted therapy and immunotherapy.

The 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan from September 16 to 19, 2026, bringing together oncology experts from around the world to explore innovative approaches to precision diagnosis and treatment. During the multiple myeloma session, Professor Aijun Liu of Beijing Chao-Yang Hospital, Capital Medical University, presented an update on a phase II clinical study of eprenetapopt combined with bispecific antibodies in relapsed/refractory multiple myeloma (RRMM). In an interview with Oncology Frontier – Hematology Frontier, Professor Liu discussed the rationale behind the study design, the underlying mechanisms, the efficacy and safety profile of the combination, and directions for future research. The interview is presented below.

The 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan from September 16 to 19, 2026, bringing together oncology experts from around the world to explore advances in precision diagnosis and treatment. During the lymphoma session, Professor Wenyu Li of Guangdong Provincial People's Hospital delivered a presentation entitled “Current Treatment Landscape and Controversies in Newly Diagnosed Mantle Cell Lymphoma (MCL).” Drawing on the 2025 EHA–EU MCL Network guidelines, the 2026 CSCO guidelines, and several pivotal clinical studies, Professor Li examined three major controversies in first-line MCL treatment: whether transplant-eligible patients still require autologous stem cell transplantation (ASCT) in the BTK inhibitor (BTKi) era; treatment options for older or transplant-ineligible patients; and precision treatment strategies for high-risk patients, including those with TP53 mutations. This article summarizes the key points of the presentation.

The treatment landscape for multiple myeloma continues to evolve with successive advances in immune-targeted therapies. As a novel class of immunotherapeutic agents, bispecific antibodies have helped address major treatment challenges in patients with relapsed or refractory disease and have become a key focus of research in multiple myeloma. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, on August 21–22. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Wenming Chen of Beijing Chao-Yang Hospital, Capital Medical University, to discuss the evolving role of bispecific antibodies in multiple myeloma, strategies for combination and sequential treatment, and the latest evidence presented at the 2026 European Hematology Association (EHA) Congress in the context of current clinical research in China. His insights offer practical guidance for the standardized, effective, and individualized use of bispecific antibodies to maximize treatment efficacy and safety for patients.

The 2026 China-France Scientific Symposium on Hematology and Immunology was held in Beijing from September 11 to 13, 2026. Building on the longstanding tradition of hematology exchanges between China and France, this year's meeting expanded its scope to the intersection of hematology and immunology, bringing together renowned experts from both countries to explore scientific advances and exchange perspectives. On this occasion, Oncology Frontier – Hematology Frontier invited Professor Li Wang from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, to discuss the treatment landscape and controversies in newly diagnosed mantle cell lymphoma (MCL). Professor Wang examined the paradigm shift in first-line MCL treatment in the era of Bruton tyrosine kinase inhibitors (BTKis) and shared valuable clinical insights into the evolving role of autologous stem cell transplantation (ASCT), treatment options for older or transplant-ineligible patients, and precision strategies for high-risk disease.